Abiomed Joins Rank Of Stocks With 95-Plus Composite Rating

Abiomed (ABMD) saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Abiomed is currently forming a consolidation, with a 387.50 entry. Look for the stock to break out in volume at least 40% higher than normal.

See How IBD Helps You Make More Money In Stocks

The stock sports a 91 EPS Rating, which means its recent quarterly and annual earnings growth tops 91% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q1, the company reported 90% EPS growth. That marks four straight quarters of rising EPS performance. Sales growth climbed 53%, up from 17% in the prior report. The company has now posted accelerating growth in each of the last four quarters.

Abiomed holds the No. 8 rank among its peers in the Medical-Products industry group. Align Technology (ALGN), Bio Rad Labs (BIOB) and Staar Surgical (STAA) are among the top 5 highly-rated stocks within the group.


Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button